Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNight sweats on Mounjaro are real, but they are almost never a sign that something is going wrong. For most people, the sweating is a short-lived response to the body adjusting to tirzepatide, typically peaking in the first few weeks after starting or after a dose increase, then fading. These medicines are prescription-only and assessed individually by a clinical prescriber — but understanding what's behind the symptom makes it far less alarming at 3am. The NHS tirzepatide patient information covers sweating within its list of reported side effects, and most cases settle without any change to treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people who contact prescribers about sweating during Mounjaro treatment worry it signals a reaction, an intolerance, or that something has gone wrong with their dose. That instinct is understandable, waking up damp in the middle of the night doesn't feel like a minor inconvenience. The reality is that sweating, including night sweats, sits within the known side-effect profile of tirzepatide and is not associated with treatment failure. Whether Mounjaro can cause night sweats is a question the evidence answers fairly clearly: yes, it can, and in most cases that's the whole story.
GLP-1 and GIP receptor agonists act on the hypothalamus, the part of the brain that governs appetite and (crucially) thermoregulation. When tirzepatide activates these pathways, it doesn't only reduce hunger signals; it also nudges how the body maintains temperature. Vasodilation (widening of blood vessels near the skin) is one result, and that can produce warmth, flushing and sweating, particularly at night when the body naturally moves through deeper temperature cycles. This is a pharmacological effect, not an allergic one.
What one of our prescribers hears most weeks: people assuming the sweating is worse than the nausea because it disturbs sleep. That's a fair concern. It doesn't make it dangerous.
Timing matters a lot here. The pattern reported most consistently is that sweating is heaviest in the 24 to 72 hours following an injection, particularly after the very first pen and after each dose increase. Mounjaro is titrated (beginning at 2.5 mg and moving up through 5, 7.5, 10, 12.5 and 15 mg) and each upward step is another adjustment point. The relationship between tirzepatide and night sweats follows this same dose-linked rhythm.
For most people, the sweating is worst in weeks two and three of a new dose and diminishes by week four, before the next dose decision arrives. If yours has followed that pattern, it is a good sign the adaptation is progressing as expected. Staying well hydrated helps; so does keeping the bedroom slightly cooler than usual. A quick check worth building into your week: note whether the sweaty nights cluster in the two or three days after your injection day. If they do, you have your answer without needing to see anyone urgently.
Some people also experience sweating if their calorie intake drops sharply on treatment, appetite suppression can mean you're eating less than your body expects, and a mild compensatory stress response can follow, including sweating. Eating enough of the right foods on Mounjaro matters for this reason, not just for nutrition.
Most night sweats on Mounjaro don't need clinical input. A few do. The MHRA has flagged acute pancreatitis as an uncommon but serious side effect of GLP-1 medicines, and severe, persistent abdominal pain that extends towards the back, particularly if accompanied by sweating and vomiting, warrants urgent medical attention rather than watchful waiting. That combination of symptoms is different from the low-grade overnight sweating described above. The broader picture of sweating on Mounjaro, including the scenarios that do need review, is covered in more detail separately.
Other reasons to mention night sweats to a prescriber: they haven't improved after six weeks on a stable dose; they're drenching rather than mild; they coincide with palpitations, significant dizziness or mood changes; or they started long after you'd been stable on a dose rather than at initiation. Those patterns could have a different cause entirely (thyroid changes, perimenopause, or something unrelated to the medicine) and are worth investigating properly. You can get in touch with our team if you're unsure whether what you're experiencing needs a clinical eye.
Suspected side effects from any medicine can be reported directly to the MHRA via the Yellow Card scheme, you don't need a GP to do it, and reports like yours genuinely inform future safety guidance.
Night sweats are among the side effects people wish they'd been warned about before starting, rather than discovered at midnight. Knowing they tend to be self-limiting, dose-linked and physiological in origin doesn't make them comfortable, but it does make them manageable. Most people work through them without any change to their treatment plan. If you're also wondering whether Mounjaro causes you to sweat more generally, not just at night, that question gets its own detailed answer.
Mounjaro (tirzepatide) is a prescription-only medicine licensed in the UK for weight management in adults meeting specific clinical criteria, assessed individually by a GPhC-registered prescriber. The NHS tirzepatide patient information page is a useful first reference for the full side-effect list, and our FAQs cover many of the questions that come up during treatment. If you're weighing up whether treatment is right for you, an overview of Mounjaro in the UK covers the evidence, the licence and the process in full.
If you'd like a prescriber to assess your suitability, check your eligibility with a free consultation, no waiting list, no referral needed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.